Center-Authored Papers

Filters: Keyword is Orchiectomy  [Clear All Filters]
C
Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon N, Wang H et al..  2011.  Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors.. Cancer research. 71(20):6503-13. Abstract
H
Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS et al..  2009.  Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.. Cancer research. 69(19):7793-802. Abstract
M
Mendiratta P, Mostaghel EA, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.  2009.  Genomic strategy for targeting therapy in castration-resistant prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(12):2022-9. Abstract
Montgomery BR, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.  2008.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.. Cancer research. 68(11):4447-54. Abstract
Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E.  2010.  Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.. BMC cancer. 10:244. Abstract
Mostaghel EA, Nelson PS.  2008.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.. Best practice & research. Clinical endocrinology & metabolism. 22(2):243-58. Abstract
Mostaghel EA, Montgomery B, Nelson PS.  2009.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.. Urologic oncology. 27(3):251-7. Abstract
S
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Sharma A, Yeow W-S, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CES, Witkiewicz AK et al..  2010.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.. The Journal of clinical investigation. 120(12):4478-92. Abstract
Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H et al..  2010.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.. The Journal of clinical investigation. 120(8):2715-30. Abstract
W
Wright JL, Kwon EM, Ostrander EA, Montgomery BR, Lin DW, Vessella R, Stanford JL, Mostaghel EA.  2011.  Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(4):619-27. Abstract